A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Sponsor
Peking University Cancer Hospital & Institute
Study ID
NCT02727309
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.

Study Details

This study is designed to evaluate the efficacy and safety of TACE combined with apatinib in treating advanced hepatocellular carcinoma. The primary endpoint is progression-free survival (PFS), 3-month PFS, 6-month PFS and 1-year PFS.

Key Dates

Start date
Oct 31, 2015
Status verified
Mar 2016
Primary completion
Dec 31, 2018
Completion
Mar 31, 2019

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib
    Patients with advanced hepatocellular carcinoma after been treated with TACE receive apatinib (750mg) daily, until disease progression or unacceptable toxicity.

Primary Outcome Measure

Progression free survival [ Time Frame: 6 months ]

Central Contacts

Related Studies